Letter to the editor: results from a Web‐based survey to identify dynapenia screening tools and risk factors

Manini, Todd M.; Clark, Brian C.

doi:10.1002/jcsm.12128

Cited by 5 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the revised version, low muscle strength (the most reliable indicator of muscle function) replaced low muscle mass as the primary parameter of sarcopenia 3 . Previous studies and reviews have also shown that muscle strength is an appropriate tool for screening sarcopenia and dynapenia 4 . For low physical activity or disability, the number and intensity of association of low muscle strength is greater than that of low muscle mass 5 .…”

Section: Introductionmentioning

confidence: 99%

Mouse models of sarcopenia: classification and evaluation

Xie

Dong-sheng

et al. 2021

J cachexia sarcopenia muscle

108

View full text Add to dashboard Cite

Sarcopenia is a progressive and widespread skeletal muscle disease that is related to an increased possibility of adverse consequences such as falls, fractures, physical disabilities and death, and its risk increases with age. With the deepening of the understanding of sarcopenia, the disease has become a major clinical disease of the elderly and a key challenge of healthy ageing. However, the exact molecular mechanism of this disease is still unclear, and the selection of treatment strategies and the evaluation of its effect are not the same. Most importantly, the early symptoms of this disease are not obvious and are easy to ignore. In addition, the clinical manifestations of each patient are not exactly the same, which makes it difficult to effectively study the progression of sarcopenia. Therefore, it is necessary to develop and use animal models to understand the pathophysiology of sarcopenia and develop therapeutic strategies. This paper reviews the mouse models that can be used in the study of sarcopenia, including ageing models, genetically engineered models, hindlimb suspension models, chemical induction models, denervation models, and immobilization models; analyses their advantages and disadvantages and application scope; and finally summarizes the evaluation of sarcopenia in mouse models.

show abstract

Section: Introductionmentioning

confidence: 99%

Mouse models of sarcopenia: classification and evaluation

Xie

Dong-sheng

et al. 2021

J cachexia sarcopenia muscle

108

View full text Add to dashboard Cite

show abstract

“…The mice were euthanasia subsequently (Figs. 1A , S2A ), and the gastrocnemius muscles were collected and subjected to histopathological tests by cross section and vertical section [ 24 ]. To better characterise the muscle size on different treatment, we conducted H&E staining on the cross section of gastrocnemius muscle and measured the area and diameter of muscle cells.…”

Section: Resultsmentioning

confidence: 99%

Clinical-grade human umbilical cord-derived mesenchymal stem cells improved skeletal muscle dysfunction in age-associated sarcopenia mice

et al. 2023

View full text Add to dashboard Cite

With the expansion of the aging population, age-associated sarcopenia (AAS) has become a severe clinical disease of the elderly and a key challenge for healthy aging. Regrettably, no approved therapies currently exist for treating AAS. In this study, clinical-grade human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) were administrated to two classic mouse models (SAMP8 mice and D-galactose-induced aging mice), and their effects on skeletal muscle mass and function were investigated by behavioral tests, immunostaining, and western blotting. Core data results showed that hUC-MSCs significantly restored skeletal muscle strength and performance in both mouse models via mechanisms including raising the expression of crucial extracellular matrix proteins, activating satellite cells, enhancing autophagy, and impeding cellular aging. For the first time, the study comprehensively evaluates and demonstrates the preclinical efficacy of clinical-grade hUC-MSCs for AAS in two mouse models, which not only provides a novel model for AAS, but also highlights a promising strategy to improve and treat AAS and other age-associated muscle diseases.

show abstract

“…In terms of the sources of these articles there were 478 separate journals that had published relevant articles in the two years analyzed, although there was some concentration with 344 of these papers (or 36%) being published in the 23 journals that published at least five cachexia articles over the two-year period. One journal, the Journal of Cachexia, Sarcopenia and Muscle ( J Cachexia Sarcopenia Muscle ), being a specialist journal in this topic, unsurprisingly published the most articles (145) 1…”

Section: Resultsmentioning

confidence: 99%

An analysis of the types of recently published research in the field of cachexia

Shewan

2017

Eur J Prev Cardiolog

View full text Add to dashboard Cite

Introduction Cachexia is a common complication of many and varied chronic disease processes, yet it has received very little attention as an area of clinical research effort until recently. We sought to survey the contemporary literature on published research into cachexia to define where it is being published and the proportion of output classified into the main types of research output. Methods I searched the PubMed listings under the topic research term "cachexia" and related terms for articles published in the calendar years of 2015 and 2016, regardless of language. Searches were conducted and relevant papers extracted by two observers, and disagreements were resolved by consensus. Results There were 954 publications, 370 of which were review articles or commentaries, 254 clinical observations or non-randomised trials, 246 original basic science reports and only 26 were randomised controlled trials. These articles were published in 478 separate journals but with 36% of them being published in a core set of 23 journals. The H-index of these papers was 25 and there were 147 papers with 10 or more citations. Of the top 100 cited papers, 25% were published in five journals. Of the top cited papers, 48% were review articles, 18% were original basic science, and 7% were randomised clinical trials. Discussion This analysis shows a steady but modest increase in publications concerning cachexia with a strong pipeline of basic science research but still a relative lack of randomised clinical trials, with none exceeding 1000 patients. Research in cachexia is still in its infancy, but the solid basic science effort offers hope that translation into randomised controlled clinical trials may eventually lead to effective therapies for this troubling and complex clinical disease process.

show abstract

Letter to the editor: results from a Web‐based survey to identify dynapenia screening tools and risk factors

Cited by 5 publications

References 6 publications

Mouse models of sarcopenia: classification and evaluation

Mouse models of sarcopenia: classification and evaluation

Clinical-grade human umbilical cord-derived mesenchymal stem cells improved skeletal muscle dysfunction in age-associated sarcopenia mice

An analysis of the types of recently published research in the field of cachexia

Contact Info

Product

Resources

About